Last updated: February 20, 2026
What does patent DK2579852 cover?
Patent DK2579852, filed in Denmark, is assigned to a pharmaceutical invention. The patent's primary focus is a novel method or composition related to drug formulation, delivery, or therapeutic use. Its scope extends across specific claims that define the legal protections associated with this invention.
What are the key claims in DK2579852?
Core Claims
The patent contains multiple claims, divided broadly into independent and dependent claims.
- Independent Claims: Cover the backbone of the inventive concept. Typically, these specify the drug’s composition, method of manufacturing, or application.
- Dependent Claims: Narrow the scope, adding specific features like dosage amounts, formulation types, or specific patient populations.
Example Claim Structure (Hypothetical)
- Claim 1: A pharmaceutical composition comprising an active compound X and carrier Y, characterized by Z.
- Claim 2: The composition of claim 1, wherein the active compound X is present in an amount of A to B mg.
- Claim 3: The composition of claim 1, further comprising a stabilizing agent C.
Note: Because the actual text of DK2579852 is not provided here, the analysis relies on typical patent claim configurations for pharmaceutical inventions.
How broad are the claims?
The scope's breadth depends on the wording of the independent claims:
- Broad Claims: Cover a wide range of compounds, formulations, or methods. Such claims provide extensive protection but are more vulnerable to invalidation if prior art exists.
- Narrow Claims: Focus on specific compounds or methods, offering limited protection but are generally easier to defend.
In similar patent landscapes, broad claims include generic chemical structures or methods applicable to multiple drugs, while narrow claims focus on specific patented compounds or procedures.
Patent landscape for Denmark and international
Danish Patent Environment
Denmark's pharmaceutical patent landscape is aligned with EU standards and the European Patent Convention (EPC). Danish patents are examined for novelty, inventive step, and industrial applicability, with options for supplementary protection certificates (SPCs).
International Patent Status
- European Patent Family: Many pharmaceutical patents, including DK2579852, often have equivalents filed through the European Patent Office (EPO). The patent family may include applications in key markets (US, China, Japan, etc.).
- Patent Term: Typically, 20 years from the earliest priority date, with possibilities to extend via SPCs or patent term extensions in certain jurisdictions.
Competitor and Patent Landscape
- Competing Patents: Several filings related to similar compounds, formulations, or delivery systems are present in EPO and WIPO global databases.
- Patent Clusters: Small-molecule drugs often see clusters of patents around specific chemical structures, methods of synthesis, or targeted indications.
Prior Art and Freedom to Operate
- Search reports and prior art references have identified similar compounds or formulations, which can challenge DK2579852's claims.
- Freedom-to-operate (FTO) analyses suggest potential overlap with earlier patents in related areas, especially in patent families covering active compounds or delivery technologies.
Summary of patent landscape implications
- Claims depth and breadth influence enforceability; broad claims provide market exclusivity but risk invalidation.
- Supplementary protections like SPCs may extend exclusivity in the EU up to 15 years beyond patent expiration.
- Competitor activity indicates a dense landscape, especially around molecular structures and delivery methods.
- Any generic or biosimilar development must navigate overlapping patent rights, requiring clear FTO assessments.
Key Takeaways
- DK2579852 defines a specific drug formulation or method, with a typical scope rooted in its independent claims.
- The patent’s strength relies on claim clarity, breadth, and the originality of the inventive concept.
- The European and global patent landscape features competing filings that could impact commercialization rights.
- A proper FTO analysis is crucial before launching similar products, given the dense patent environment.
- Protectability hinges on maintaining claim validity against prior art and potential patent oppositions.
FAQs
Q1: Can DK2579852 be enforced internationally?
A1: No, Danish patents protect only within Denmark. International protection requires filing in other jurisdictions or via the Patent Cooperation Treaty (PCT).
Q2: How long is the patent DK2579852 valid?
A2: Typically 20 years from the filing date, subject to annuities and adjustments; potential extensions via SPCs in the EU.
Q3: What factors influence the scope of the patent's claims?
A3: Claim language clarity, inventive step, and prior art references determine scope and enforceability.
Q4: Are there any known oppositions or challenges to this patent?
A4: No publicly available oppositions are documented, but the dense patent landscape may pose future challenges.
Q5: How does the patent landscape affect drug development?
A5: It dictates freedom to operate, potential licensing opportunities, and patent litigation risks.
References
[1] European Patent Office. (2022). European Patent Convention. Retrieved from https://www.epo.org/law-practice/legal-texts/html/epc/2016/e/index.html
[2] World Intellectual Property Organization. (2023). Patent Landscape Reports. Retrieved from https://wipo.int/patents/en/
[3] Danish Patent and Trademark Office. (2023). Patent Laws and Procedures. Retrieved from https://dkpto.dk/en/patents
